A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells. / Dagg, Rebecca A.; Zonderland, Gijs; Lombardi, Emilia Puig; Rossetti, Giacomo G.; Groelly, Florian J.; Barroso, Sonia; Tacconi, Eliana M.C.; Wright, Benjamin; Lockstone, Helen; Aguilera, Andrés; Halazonetis, Thanos D.; Tarsounas, Madalena.

In: Nature Communications, Vol. 12, No. 1, 4919, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Dagg, RA, Zonderland, G, Lombardi, EP, Rossetti, GG, Groelly, FJ, Barroso, S, Tacconi, EMC, Wright, B, Lockstone, H, Aguilera, A, Halazonetis, TD & Tarsounas, M 2021, 'A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells', Nature Communications, vol. 12, no. 1, 4919. https://doi.org/10.1038/s41467-021-25215-0

APA

Dagg, R. A., Zonderland, G., Lombardi, E. P., Rossetti, G. G., Groelly, F. J., Barroso, S., Tacconi, E. M. C., Wright, B., Lockstone, H., Aguilera, A., Halazonetis, T. D., & Tarsounas, M. (2021). A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells. Nature Communications, 12(1), [4919]. https://doi.org/10.1038/s41467-021-25215-0

Vancouver

Dagg RA, Zonderland G, Lombardi EP, Rossetti GG, Groelly FJ, Barroso S et al. A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells. Nature Communications. 2021;12(1). 4919. https://doi.org/10.1038/s41467-021-25215-0

Author

Dagg, Rebecca A. ; Zonderland, Gijs ; Lombardi, Emilia Puig ; Rossetti, Giacomo G. ; Groelly, Florian J. ; Barroso, Sonia ; Tacconi, Eliana M.C. ; Wright, Benjamin ; Lockstone, Helen ; Aguilera, Andrés ; Halazonetis, Thanos D. ; Tarsounas, Madalena. / A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells. In: Nature Communications. 2021 ; Vol. 12, No. 1.

Bibtex

@article{6a4888adbc8e4ae2b3ea374dc2f657a2,
title = "A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells",
abstract = "BRCA1 or BRCA2 germline mutations predispose to breast, ovarian and other cancers. High-throughput sequencing of tumour genomes revealed that oncogene amplification and BRCA1/2 mutations are mutually exclusive in cancer, however the molecular mechanism underlying this incompatibility remains unknown. Here, we report that activation of β-catenin, an oncogene of the WNT signalling pathway, inhibits proliferation of BRCA1/2-deficient cells. RNA-seq analyses revealed β-catenin-induced discrete transcriptome alterations in BRCA2-deficient cells, including suppression of CDKN1A gene encoding the CDK inhibitor p21. This accelerates G1/S transition, triggering illegitimate origin firing and DNA damage. In addition, β-catenin activation accelerates replication fork progression in BRCA2-deficient cells, which is critically dependent on p21 downregulation. Importantly, we find that upregulated p21 expression is essential for the survival of BRCA2-deficient cells and tumours. Thus, our work demonstrates that β-catenin toxicity in cancer cells with compromised BRCA1/2 function is driven by transcriptional alterations that cause aberrant replication and inflict DNA damage.",
author = "Dagg, {Rebecca A.} and Gijs Zonderland and Lombardi, {Emilia Puig} and Rossetti, {Giacomo G.} and Groelly, {Florian J.} and Sonia Barroso and Tacconi, {Eliana M.C.} and Benjamin Wright and Helen Lockstone and Andr{\'e}s Aguilera and Halazonetis, {Thanos D.} and Madalena Tarsounas",
note = "Funding Information: We are grateful to members of M.T. laboratory for critical reading of the manuscript and valuable feedback. Andr{\'e}s Aguilera{\textquoteright}s laboratory is funded by the European Research Council (grant ERC2014 AdG669898 TARLOOP). The work in Thanos Halazonetis{\textquoteright} laboratory was supported by grants from the Swiss National Science Foundation (182487) and the European Commission (ERC project REPLISTRESS). Research in Madalena Tarsounas{\textquoteright} laboratory is supported by Cancer Research UK and University of Oxford. This project has received funding from long-term EMBO non-stipendiary fellowship (ALTF 1044-2019), the European Union{\textquoteright}s Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie grant agreement No. 722729 and grant agreement No. 886045. M.T. was the recipient of a Mayent-Rothschild-Institute Curie Award. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
doi = "10.1038/s41467-021-25215-0",
language = "English",
volume = "12",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "nature publishing group",
number = "1",

}

RIS

TY - JOUR

T1 - A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells

AU - Dagg, Rebecca A.

AU - Zonderland, Gijs

AU - Lombardi, Emilia Puig

AU - Rossetti, Giacomo G.

AU - Groelly, Florian J.

AU - Barroso, Sonia

AU - Tacconi, Eliana M.C.

AU - Wright, Benjamin

AU - Lockstone, Helen

AU - Aguilera, Andrés

AU - Halazonetis, Thanos D.

AU - Tarsounas, Madalena

N1 - Funding Information: We are grateful to members of M.T. laboratory for critical reading of the manuscript and valuable feedback. Andrés Aguilera’s laboratory is funded by the European Research Council (grant ERC2014 AdG669898 TARLOOP). The work in Thanos Halazonetis’ laboratory was supported by grants from the Swiss National Science Foundation (182487) and the European Commission (ERC project REPLISTRESS). Research in Madalena Tarsounas’ laboratory is supported by Cancer Research UK and University of Oxford. This project has received funding from long-term EMBO non-stipendiary fellowship (ALTF 1044-2019), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722729 and grant agreement No. 886045. M.T. was the recipient of a Mayent-Rothschild-Institute Curie Award. Publisher Copyright: © 2021, The Author(s).

PY - 2021

Y1 - 2021

N2 - BRCA1 or BRCA2 germline mutations predispose to breast, ovarian and other cancers. High-throughput sequencing of tumour genomes revealed that oncogene amplification and BRCA1/2 mutations are mutually exclusive in cancer, however the molecular mechanism underlying this incompatibility remains unknown. Here, we report that activation of β-catenin, an oncogene of the WNT signalling pathway, inhibits proliferation of BRCA1/2-deficient cells. RNA-seq analyses revealed β-catenin-induced discrete transcriptome alterations in BRCA2-deficient cells, including suppression of CDKN1A gene encoding the CDK inhibitor p21. This accelerates G1/S transition, triggering illegitimate origin firing and DNA damage. In addition, β-catenin activation accelerates replication fork progression in BRCA2-deficient cells, which is critically dependent on p21 downregulation. Importantly, we find that upregulated p21 expression is essential for the survival of BRCA2-deficient cells and tumours. Thus, our work demonstrates that β-catenin toxicity in cancer cells with compromised BRCA1/2 function is driven by transcriptional alterations that cause aberrant replication and inflict DNA damage.

AB - BRCA1 or BRCA2 germline mutations predispose to breast, ovarian and other cancers. High-throughput sequencing of tumour genomes revealed that oncogene amplification and BRCA1/2 mutations are mutually exclusive in cancer, however the molecular mechanism underlying this incompatibility remains unknown. Here, we report that activation of β-catenin, an oncogene of the WNT signalling pathway, inhibits proliferation of BRCA1/2-deficient cells. RNA-seq analyses revealed β-catenin-induced discrete transcriptome alterations in BRCA2-deficient cells, including suppression of CDKN1A gene encoding the CDK inhibitor p21. This accelerates G1/S transition, triggering illegitimate origin firing and DNA damage. In addition, β-catenin activation accelerates replication fork progression in BRCA2-deficient cells, which is critically dependent on p21 downregulation. Importantly, we find that upregulated p21 expression is essential for the survival of BRCA2-deficient cells and tumours. Thus, our work demonstrates that β-catenin toxicity in cancer cells with compromised BRCA1/2 function is driven by transcriptional alterations that cause aberrant replication and inflict DNA damage.

U2 - 10.1038/s41467-021-25215-0

DO - 10.1038/s41467-021-25215-0

M3 - Journal article

C2 - 34389725

AN - SCOPUS:85112729865

VL - 12

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4919

ER -

ID: 306683320